WO2006024953A3 - Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues - Google Patents
Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues Download PDFInfo
- Publication number
- WO2006024953A3 WO2006024953A3 PCT/IB2005/002939 IB2005002939W WO2006024953A3 WO 2006024953 A3 WO2006024953 A3 WO 2006024953A3 IB 2005002939 W IB2005002939 W IB 2005002939W WO 2006024953 A3 WO2006024953 A3 WO 2006024953A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- growth hormone
- human growth
- preparation
- methods
- polyethylene glycol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200700380A EA200700380A1 (ru) | 2004-08-31 | 2005-08-25 | Конъюгаты глицеринразветвлённого полиэтиленгликоля - гормона роста человека, способ их получения и способы их применения |
EP05784225A EP1789092A2 (fr) | 2004-08-31 | 2005-08-25 | Conjugués de l'hormone de croissance humaine avec du polyéthylèneglycol ramifié à l'aide de glycérol, procédé de sa préparation, et méthode de son utilisation. |
JP2007529040A JP2008511610A (ja) | 2004-08-31 | 2005-08-25 | グリセロール分岐のポリエチレングリコール−ヒト成長ホルモン結合体、それらの製造方法及び使用方法 |
BRPI0515118-0A BRPI0515118A (pt) | 2004-08-31 | 2005-08-25 | conjugados de hormÈnio do crescimento humano com polietileno glicol |
AU2005278903A AU2005278903A1 (en) | 2004-08-31 | 2005-08-25 | Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof |
MX2007002441A MX2007002441A (es) | 2004-08-31 | 2005-08-25 | Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos. |
AP2007003919A AP2007003919A0 (en) | 2004-08-31 | 2005-08-25 | Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof |
CA002577999A CA2577999A1 (fr) | 2004-08-31 | 2005-08-25 | Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues |
IL181085A IL181085A0 (en) | 2004-08-31 | 2007-01-31 | Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof |
TNP2007000078A TNSN07078A1 (fr) | 2004-08-31 | 2007-02-27 | Conjugues d'hormone de croissance humaine avec un polyethyleneglycol ramifie avec du glycerol, procede pour leur preparation et methodes pour leur utilisation |
NO20071322A NO20071322L (no) | 2004-08-31 | 2007-03-09 | Humane veksthormonkonjugater av glyserolforgrenet polyetylenglycol, fremgangsmate for dens fremstilling og fremgangsmate for anvendelse derav |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60594504P | 2004-08-31 | 2004-08-31 | |
US60/605,945 | 2004-08-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006024953A2 WO2006024953A2 (fr) | 2006-03-09 |
WO2006024953A3 true WO2006024953A3 (fr) | 2007-01-18 |
Family
ID=35708806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2005/002939 WO2006024953A2 (fr) | 2004-08-31 | 2005-08-25 | Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1789092A2 (fr) |
JP (1) | JP2008511610A (fr) |
KR (1) | KR20070042567A (fr) |
CN (1) | CN101010105A (fr) |
AP (1) | AP2007003919A0 (fr) |
AR (1) | AR050851A1 (fr) |
AU (1) | AU2005278903A1 (fr) |
BR (1) | BRPI0515118A (fr) |
CA (1) | CA2577999A1 (fr) |
CR (1) | CR8942A (fr) |
EA (1) | EA200700380A1 (fr) |
EC (1) | ECSP077281A (fr) |
GT (1) | GT200500235A (fr) |
IL (1) | IL181085A0 (fr) |
MA (1) | MA28908B1 (fr) |
MX (1) | MX2007002441A (fr) |
NL (1) | NL1029828C2 (fr) |
NO (1) | NO20071322L (fr) |
PE (1) | PE20060654A1 (fr) |
TN (1) | TNSN07078A1 (fr) |
TW (1) | TW200621291A (fr) |
UY (1) | UY29088A1 (fr) |
WO (1) | WO2006024953A2 (fr) |
ZA (1) | ZA200701802B (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU751898B2 (en) | 1997-07-14 | 2002-08-29 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
AU775937B2 (en) | 1999-01-14 | 2004-08-19 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
EP1834963A1 (fr) * | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Conjugues de proteines et de dipolymeres et leurs procedes de preparation |
US20090117077A1 (en) * | 2006-05-12 | 2009-05-07 | Dong-A Pharm. Co., Ltd. | Polyethylene glycol-interferon alpha conjugate |
JP2008069073A (ja) * | 2006-09-12 | 2008-03-27 | Yokohama Tlo Co Ltd | ラクトフェリン複合体及びその製造方法 |
KR101079993B1 (ko) * | 2006-11-17 | 2011-11-04 | 동아제약주식회사 | 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체 |
CL2008002399A1 (es) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
RU2483081C2 (ru) * | 2008-07-23 | 2013-05-27 | Ханми Сайенс Ко.,Лтд.,Kr | Полипептидный комплекс, содержащий непептидильный полимер, обладающий тремя функциональными концами |
UA104146C2 (ru) | 2008-07-31 | 2014-01-10 | Фармаиссеншиа Корп. | ПОЛИМЕРНЫЕ КОНЪЮГАТЫ ФРАГМЕНТОВ ИНТЕРФЕРОНА-β, ЭРИТРОПОЭТИНА И ГОРМОНА РОСТА |
SI2340271T1 (sl) * | 2008-10-10 | 2019-08-30 | Polyactiva Pty Ltd. | Konjugati polimer-bioaktivnega sredstva |
KR101726715B1 (ko) * | 2008-10-10 | 2017-04-13 | 폴리액티바 피티와이 리미티드 | 생분해성 폴리머-생물활성 모이어티 공액체 |
US8535655B2 (en) | 2008-10-10 | 2013-09-17 | Polyactiva Pty Ltd. | Biodegradable polymer—bioactive moiety conjugates |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
NZ628987A (en) | 2009-02-03 | 2015-11-27 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
CN102612376A (zh) | 2009-08-06 | 2012-07-25 | 诺沃-诺迪斯克保健股份有限公司 | 具有延长的体内功效的生长激素 |
CN101831067A (zh) * | 2010-05-31 | 2010-09-15 | 王二新 | 聚乙二醇脂类缀合物及其在制备药物中的应用 |
EP2446898A1 (fr) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Utilisation de l'hormone de croissance pour améliorer la réponse immunitaire chez des patients immunodéprimés |
CN102367290B (zh) * | 2011-04-26 | 2013-05-08 | 厦门赛诺邦格生物科技有限公司 | 链官能化的多级支化聚乙二醇及其合成方法 |
DK2947111T3 (en) * | 2013-01-17 | 2018-05-07 | Xiamen Sinopeg Biotech Co Ltd | MONOFUNCTIONAL BRANCHED POLYETHYLENE LYCOL AND BIORELATED SUBSTANCE MODIFIED BY SAME |
CN104877127B (zh) | 2015-06-23 | 2017-11-10 | 厦门赛诺邦格生物科技股份有限公司 | 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质 |
ES2966888T3 (es) | 2014-11-06 | 2024-04-24 | Pharmaessentia Corp | Régimen de dosificación para el interferón pegilado |
CN111801120A (zh) | 2017-12-29 | 2020-10-20 | 豪夫迈·罗氏有限公司 | 用于提供聚乙二醇化蛋白质组合物的方法 |
EP3731871B1 (fr) * | 2017-12-29 | 2023-10-04 | F. Hoffmann-La Roche AG | Procédé de fournir des protéines pégylée |
JP7227633B2 (ja) * | 2017-12-29 | 2023-02-22 | エフ. ホフマン-ラ ロシュ エージー. | Peg化タンパク質組成物を提供するための方法 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000109A1 (fr) * | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance |
EP0839849A1 (fr) * | 1996-11-05 | 1998-05-06 | Nof Corporation | Procédé pour la préparation d'un dérivé de polyoxyalkylène substitué par un groupe succinimidyl |
WO1999003887A1 (fr) * | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derives d'hormone de croissance et proteines associees |
JPH11228685A (ja) * | 1998-02-12 | 1999-08-24 | Nof Corp | カルボキシル基含有ポリオキシアルキレン化合物 |
WO2000042175A1 (fr) * | 1999-01-14 | 2000-07-20 | Bolder Biotechnology Inc. | Techniques permettant de produire des proteines contenant des residus cysteine libres |
WO2003044056A2 (fr) * | 2001-11-20 | 2003-05-30 | Pharmacia Corporation | Conjugues de l'hormone de croissance humaine chimiquement modifiee |
WO2004022630A2 (fr) * | 2002-09-09 | 2004-03-18 | Nektar Therapeutics Al, Corporation | Alcanales polymeres solubles dans l'eau |
WO2004046222A1 (fr) * | 2002-11-20 | 2004-06-03 | Nof Corporation | Substance biologique modifiee, procede permettan de produire cette substance et produit intermediaire |
WO2004060406A2 (fr) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Reactifs polymeres comprenant une cetone ou un groupe fonctionnel apparente |
WO2005000360A2 (fr) * | 2003-05-23 | 2005-01-06 | Nektar Therapeutics Al, Corporation | Derives polymeres ayant des agencements d'atomes particuliers |
-
2005
- 2005-08-25 CN CNA2005800291171A patent/CN101010105A/zh active Pending
- 2005-08-25 MX MX2007002441A patent/MX2007002441A/es unknown
- 2005-08-25 JP JP2007529040A patent/JP2008511610A/ja active Pending
- 2005-08-25 KR KR1020077004912A patent/KR20070042567A/ko not_active Application Discontinuation
- 2005-08-25 WO PCT/IB2005/002939 patent/WO2006024953A2/fr active Application Filing
- 2005-08-25 AU AU2005278903A patent/AU2005278903A1/en not_active Abandoned
- 2005-08-25 CA CA002577999A patent/CA2577999A1/fr not_active Abandoned
- 2005-08-25 BR BRPI0515118-0A patent/BRPI0515118A/pt not_active IP Right Cessation
- 2005-08-25 AP AP2007003919A patent/AP2007003919A0/xx unknown
- 2005-08-25 EA EA200700380A patent/EA200700380A1/ru unknown
- 2005-08-25 EP EP05784225A patent/EP1789092A2/fr not_active Withdrawn
- 2005-08-26 PE PE2005000991A patent/PE20060654A1/es not_active Application Discontinuation
- 2005-08-29 UY UY29088A patent/UY29088A1/es not_active Application Discontinuation
- 2005-08-29 AR ARP050103612A patent/AR050851A1/es unknown
- 2005-08-30 GT GT200500235A patent/GT200500235A/es unknown
- 2005-08-30 NL NL1029828A patent/NL1029828C2/nl not_active IP Right Cessation
- 2005-08-30 TW TW094129583A patent/TW200621291A/zh unknown
-
2007
- 2007-01-31 IL IL181085A patent/IL181085A0/en unknown
- 2007-02-26 CR CR8942A patent/CR8942A/es not_active Application Discontinuation
- 2007-02-27 TN TNP2007000078A patent/TNSN07078A1/fr unknown
- 2007-02-27 EC EC2007007281A patent/ECSP077281A/es unknown
- 2007-02-28 ZA ZA200701802A patent/ZA200701802B/xx unknown
- 2007-02-28 MA MA29724A patent/MA28908B1/fr unknown
- 2007-03-09 NO NO20071322A patent/NO20071322L/no not_active Application Discontinuation
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000109A1 (fr) * | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance |
EP0839849A1 (fr) * | 1996-11-05 | 1998-05-06 | Nof Corporation | Procédé pour la préparation d'un dérivé de polyoxyalkylène substitué par un groupe succinimidyl |
WO1999003887A1 (fr) * | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derives d'hormone de croissance et proteines associees |
JPH11228685A (ja) * | 1998-02-12 | 1999-08-24 | Nof Corp | カルボキシル基含有ポリオキシアルキレン化合物 |
WO2000042175A1 (fr) * | 1999-01-14 | 2000-07-20 | Bolder Biotechnology Inc. | Techniques permettant de produire des proteines contenant des residus cysteine libres |
WO2003044056A2 (fr) * | 2001-11-20 | 2003-05-30 | Pharmacia Corporation | Conjugues de l'hormone de croissance humaine chimiquement modifiee |
WO2004022630A2 (fr) * | 2002-09-09 | 2004-03-18 | Nektar Therapeutics Al, Corporation | Alcanales polymeres solubles dans l'eau |
WO2004046222A1 (fr) * | 2002-11-20 | 2004-06-03 | Nof Corporation | Substance biologique modifiee, procede permettan de produire cette substance et produit intermediaire |
WO2004060406A2 (fr) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Reactifs polymeres comprenant une cetone ou un groupe fonctionnel apparente |
WO2005000360A2 (fr) * | 2003-05-23 | 2005-01-06 | Nektar Therapeutics Al, Corporation | Derives polymeres ayant des agencements d'atomes particuliers |
Non-Patent Citations (4)
Title |
---|
CLARK R ET AL: "Long-acting growth hormones produced by conjugation with polyethylene glycol", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 271, no. 36, 6 September 1996 (1996-09-06), pages 21969 - 21977, XP002216386, ISSN: 0021-9258 * |
DATABASE WPI Section Ch Week 199944, Derwent World Patents Index; Class A25, AN 1999-522765, XP002335203 * |
DATABASE WPI Section Ch Week 200442, Derwent World Patents Index; Class A25, AN 2004-449738, XP002335204 * |
KNAUF M J ET AL: "Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers", JOURNAL OF BIOLOGICAL CHEMISTRY 1988 UNITED STATES, vol. 263, no. 29, 1988, pages 15064 - 15070, XP002256084, ISSN: 0021-9258 * |
Also Published As
Publication number | Publication date |
---|---|
EP1789092A2 (fr) | 2007-05-30 |
TW200621291A (en) | 2006-07-01 |
NO20071322L (no) | 2007-05-29 |
AU2005278903A1 (en) | 2006-03-09 |
IL181085A0 (en) | 2007-07-04 |
AP2007003919A0 (en) | 2007-02-28 |
CN101010105A (zh) | 2007-08-01 |
UY29088A1 (es) | 2006-03-31 |
NL1029828A1 (nl) | 2006-03-01 |
EA200700380A1 (ru) | 2007-10-26 |
TNSN07078A1 (fr) | 2008-06-02 |
CA2577999A1 (fr) | 2006-03-09 |
GT200500235A (es) | 2006-03-21 |
PE20060654A1 (es) | 2006-08-12 |
ZA200701802B (en) | 2008-08-27 |
MA28908B1 (fr) | 2007-10-01 |
JP2008511610A (ja) | 2008-04-17 |
AR050851A1 (es) | 2006-11-29 |
MX2007002441A (es) | 2007-05-04 |
ECSP077281A (es) | 2007-03-29 |
WO2006024953A2 (fr) | 2006-03-09 |
NL1029828C2 (nl) | 2006-10-20 |
BRPI0515118A (pt) | 2008-07-01 |
KR20070042567A (ko) | 2007-04-23 |
CR8942A (es) | 2007-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006024953A3 (fr) | Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues | |
WO2006014673A3 (fr) | Conjugues insuline-oligomere, preparations et utilisations de ceux-ci | |
WO2006004959A3 (fr) | Peg-interferon alpha-1b | |
WO2008027854A3 (fr) | Compositions pharmaceutiques à hormone de croissance humaine pour délivrance par voie orale | |
WO2005097202A3 (fr) | Nouvelle utilisation et methode | |
DE602005001445D1 (de) | N-terminal monopegylierte menschliche wachstumshormon-konjugate, verfahren zu ihrer herstellung und ihre anwendung | |
WO2005049061A8 (fr) | Formulations peptidiques a base de propylene glycol optimales pour la production et l'utilisation dans des dispositifs d'injection | |
WO2006071840A3 (fr) | Formulations d'hormone de croissance humaine comportant un acide amine code de maniere non naturelle | |
WO2003022210A3 (fr) | Compositions pharmaceutiques de conjugues medicament-oligomere et methodes therapeutiques associees | |
WO2005120461A3 (fr) | Formulations liposomales renfermant de la dihydrosphingomyeline, et procedes d'utilisation correspondants | |
WO2005080338A3 (fr) | Nouvelles compositions pharmaceutiques a base d'esters d'acide benzilique et proteines de fusion du recepteur tnf solubles | |
WO2002072636A8 (fr) | Cristaux d'anticorps entiers et fragments d'anticorps et methodes de fabrication et d'utilisation associees | |
WO2006138608A3 (fr) | Compositions pharmaceutiques et leur utilisation | |
DK1180121T3 (da) | Langtidsvirkende insulinotrope peptider | |
WO2006050930A3 (fr) | Composes a molecules conjugues presentant une activite d'absorption de cellules ameliorees | |
EA200900451A1 (ru) | Способ получения композиции эстрадиола с медленным высвобождением ( варианты ), микросферы эстрадиола и холестерина и способ для одновременной контрацепции и гормонозамещения | |
WO2005065708A3 (fr) | Formulations de proteines hydrophobes dans une composition immunogenique a tolerabilite amelioree | |
WO2003079993A3 (fr) | Preparations d'hormone de croissance humaine (hch) destinees a etre administrees par voie pulmonaire | |
WO2007050121A3 (fr) | Hemoglobine pegylee a site specifique, procede de preparation afferent et utilisations associees | |
IL180900A0 (en) | Immunogenic complexes, preparation method thereof and use of same in pharmaceutical compositions | |
WO2005041881A8 (fr) | Conjugues taxoide/acide gras et preparations les contenant | |
WO2007104768A3 (fr) | Conjugués de protéines di-polymères et leurs procédés d'élaboration | |
WO2007042983A3 (fr) | Utilisation de fluridone comme agent anti-inflammatoire | |
CA2436537A1 (fr) | Nouvelles compositions pharmaceutiques | |
WO2005048993A3 (fr) | Minimisation de l'oxydation des medicaments dans des formulations pharmaceutiques renfermant des excipients irradies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 181085 Country of ref document: IL Ref document number: 2005278903 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 553064 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005784225 Country of ref document: EP Ref document number: 1056/DELNP/2007 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2005278903 Country of ref document: AU Date of ref document: 20050825 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 07017969 Country of ref document: CO |
|
WWP | Wipo information: published in national office |
Ref document number: 2005278903 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007500458 Country of ref document: PH Ref document number: 2577999 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2007-008942 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007529040 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 9898 Country of ref document: GE Ref document number: MX/a/2007/002441 Country of ref document: MX Ref document number: 1020077004912 Country of ref document: KR Ref document number: 200700380 Country of ref document: EA Ref document number: 200580029117.1 Country of ref document: CN Ref document number: DZP2007000150 Country of ref document: DZ |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005784225 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0515118 Country of ref document: BR |